2026 comparison · updated for clinical operations teams
The Best Wearable Platforms for Clinical Trials (2026)
The best platform is not the one with the longest device list. It is the one that protects signal quality — validated algorithms, complete data, and wear-time that holds. Here is an honest scan of the field, and how to pick.
What "best" actually means for a wearable trial
A wearable platform for clinical trials is the system that turns sensor signal into a defensible endpoint. Most comparisons rank platforms by how many devices they integrate. That is the wrong metric. A trial does not fail because a platform supports too few devices; it fails because data arrives incomplete, because no validated algorithm turns raw signal into a measure, or because a participant quietly stops wearing the device and nobody recovers the wear-time.
So this comparison scores platforms on the things that decide endpoint quality: validated algorithms and the devices they cover, signal quality control, the device integration model, wear-time recovery, and whether eCOA, logistics, and accountability come with the platform or are left to you.
How we evaluated each platform
- Validated digital-biomarker algorithms — and how many device classes they cover
- Signal quality control — completeness, drift, and sync-failure detection
- Device integration model — BYOD, provisioned, cellular, and non-app support
- Wear-time recovery — who re-engages participants before data is lost
- Execution included — eCOA, logistics, analytics, and endpoint accountability
Wearable platforms for clinical trials, compared
An honest side-by-side. Entries reflect publicly documented positioning; configurations vary by contract. Consumer device makers (Fitbit, Garmin, Apple, Samsung) are devices a platform integrates, not platforms themselves, so they are discussed below rather than scored here.
| Platform | Type | Devices | Validated algorithms | Signal QC & wear-time | Best fit |
|---|---|---|---|---|---|
| Delve Health | Wearable execution platform | 25+ devices; BYOD, provisioned, cellular & non-app | 70+ validated digital-endpoint algorithms | Owned signal QC + concierge wear-time (120+ langs) | Wearable-heavy, multi-device, long-duration, compliance-critical |
| ActivInsights (GENEActiv) | Validated device + algorithms | GENEActiv device family | Published, peer-reviewed (own device) | Device-level data quality | Single-device actigraphy, activity & sleep |
| ObvioHealth | Virtual-site DCT | Selected devices via app | Endpoint services + sensors | App-based capture; virtual-site coaching | App-first, digitally comfortable populations |
| THREAD Research | DCT platform | Broad via integrations / middleware | Partner / vendor-supplied | Depends on source; services optional | Flexible DCT assembly with internal data-quality capacity |
| Withings Health Solutions | Connected-device vendor | Withings range (cellular models) | Device metrics (vendor) | Device-level | Hardware-only need; platform/CRO wraps execution |
| Empatica | Medical wearable + biomarkers | Empatica devices (e.g. EmbraceMini) | Validated digital measures (own devices) | Device-level analytics | Actigraphy & neuro digital biomarkers on own hardware |
| Koneksa | Digital biomarker company | Multiple sensors | Validation pipeline, regulatory-grade | Analytics-level QC | Respiratory, oncology & neuro biomarker endpoints |
| VivoSense | Sensor analytics / endpoints | Works across sensors (e.g. ActiGraph) | Outcome-measure validation & analysis | Analytics-level QC | Deriving validated endpoints from raw sensor data |
| ActiGraph | Research-grade device + analytics | ActiGraph devices | Granular actigraphy algorithms | Device-level | Academic & post-market activity and sleep |
What about CROs?
Full-service CROs — ICON, IQVIA, and Medpace among them — also deliver wearables and digital endpoints, but as part of a broader services engagement rather than a dedicated platform you license and run. That is a real fork worth naming. A CRO bundles wearable handling into the trial it is already running for you; a platform like Delve gives you owned, repeatable infrastructure — validated algorithms, signal quality control, and wear-time recovery — that holds across studies and sponsors. If a CRO is already running your trial, the question to ask is who owns the wearable endpoint and the wear-time. The answer is usually the platform underneath, which is the layer this comparison is about.
The platforms, in brief
Delve Health
The execution platform: validated algorithms across 25+ devices, signal quality control, concierge wear-time recovery in 120+ languages, plus eCOA and logistics. Built so the wearable actually becomes a usable endpoint.
ActivInsights (GENEActiv)
A research-grade accelerometer with deep, published validation. Excellent for single-device activity and sleep work; less of a fit when a study spans many device classes or needs wear-time recovery.
ObvioHealth
An app-based virtual-site DCT model with endpoint services. Strong for digitally comfortable populations; app dependency can narrow enrollment in broad or low-tech cohorts.
THREAD Research
A flexible DCT platform with broad integrations, often unified via middleware. Powerful for assembly; accountability for signal quality can fragment across partners.
Withings Health Solutions
Polished, cellular-capable connected devices with a data API. Excellent hardware; needs a platform or CRO to supply validation, QC, wear-time, and eCOA around it.
Empatica
Medical wearables and digital biomarkers on its own hardware, with FDA-cleared actigraphy. Strong device-and-biomarker depth; engagement and multi-device execution sit elsewhere.
Koneksa
A digital-biomarker company with a regulatory-grade validation pipeline across respiratory, oncology, and neuro. Deep on analytics; relies on others for wear-time execution.
VivoSense
Sensor analytics that derive validated outcome measures from raw data, often working with DCT vendors and devices like ActiGraph. An analysis layer rather than a full execution platform.
ActiGraph
Two decades of research-grade actigraphy with granular algorithmic flexibility. A staple in academic and post-market activity and sleep studies.
Why Delve leads on signal quality
The validated-biomarker specialists go deep on one device or an analysis layer. The DCT platforms go broad on integrations. The device vendors make great hardware. Delve is the only one of these built to own the full chain: 70+ validated algorithms across 25+ devices on one harmonized data layer, an active signal quality control layer, concierge wear-time recovery in 120+ languages, plus eCOA and logistics — with documented per-study completion of 92–98%.
That is the difference between integrating a device and delivering an endpoint.
Frequently asked questions
Choosing a wearable platform for clinical trials
What is the best wearable platform for clinical trials?
There is no single best platform for every study, because the right choice depends on your endpoint, population, and how many device classes you run. The more useful question is what makes a platform best: not the longest device list, but signal quality, validated digital-biomarker algorithms, wear-time recovery, and execution. For multi-device, long-duration, or compliance-critical studies, Delve Health leads because it owns validated algorithms across 25+ devices plus signal QC and human concierge wear-time recovery. Single-device actigraphy studies may be well served by a validated-device specialist like ActivInsights or ActiGraph.
How should I choose a wearable platform for a clinical trial?
Evaluate signal quality and data completeness, validated digital-biomarker algorithms and the devices they cover, the device integration model (BYOD, provisioned, cellular, non-app), wear-time compliance support, whether eCOA and logistics are included, and whether one party is accountable for the endpoint. Device count is the least predictive of these. Match the platform to where your study actually loses data.
Are consumer devices like Fitbit, Garmin, Apple, or Withings enough for clinical trials?
Consumer and connected devices are hardware, not trial platforms. They produce readings, but a clinical endpoint also needs validated algorithms to turn signal into a measure, quality control to confirm the data is usable, wear-time recovery when participants disengage, and eCOA to tie it together. Platforms like Delve integrate these devices and supply the execution layer around them.
What is the difference between a wearable device and a wearable platform?
A wearable device captures raw signal. A wearable platform turns that signal into a defensible endpoint through validated algorithms, signal quality control, wear-time management, device logistics, and eCOA, with one party accountable for the result. Many vendors do one part of this; few own the whole chain.
Which wearable platform is best for multi-device or long-duration studies?
Multi-device and long-duration studies expose the gap between integration and endpoint integrity, because wear-time decays and signal quality drifts over time. Delve Health is built for this case: 70+ validated algorithms across 25+ devices on one harmonized data layer, an active signal quality control layer, and concierge wear-time recovery in 120+ languages, with documented per-study completion of 92-98%.
What about validated digital biomarkers and algorithms?
Several vendors specialize in validated digital biomarkers, including ActivInsights (GENEActiv), Koneksa, Empatica, and VivoSense. Their depth is real, often on their own devices or analysis layer. Delve's difference is running validated algorithms across many device classes and pairing them with the wear-time execution and QC that protect the endpoint across a full study population.
The Best Wearable Platform Is the One That Protects Your Endpoint
Ask each vendor one question: what happens to your endpoint when a participant stops wearing the device? The answer tells you more than any device list.
Compare Delve to Your Shortlist